Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Especificación
Tipo de cuenta
CFD Trading: MetaTrader 5
CFD Trading: MetaTrader 5
Investing: Web
Comisiones
0.1%
Horario de operaciones (UTC)
Abrir ahoraCerradoCierre elApertura el
a las
-
El horario de apertura del mercado se indica según su zona horaria local
(UTC)
Abre una cuenta y comienza a invertir con Metadoro ahora. Invite a amigos y obtenga remuneración por su comercio activo. Puede obtener más información sobre el programa de afiliados en su Área Personal.
Gracias por visitarnos metadoro.com. Este sitio web es administrado por RHC Investments, que está autorizada y regulada como Agente de Inversiones por la Comisión de Servicios Financieros de Mauricio con el número de licencia C115015381. Mauricio no forma parte del marco regulatorio europeo y no está dentro del alcance (entre otros) de la Directiva sobre Mercados de Instrumentos Financieros (MiFID) II.
Al continuar, confirma que la decisión se toma de forma independiente y por iniciativa propia y exclusiva y que RHC Investments no ha realizado ninguna solicitud o recomendación.
¡Personalice la suscripción a su manera!Create a Newsletter
Customize your subscriptions the way you want!
Analytics
Get notified upon new posts
Select category
Price alerts
Detección oportuna de altibajos del mercado, fluctuaciones, etc.
Select category
Alert method
All categoriescategoriesAll instrumentsinstrumentssearchNothing found